PepGen (PEPG) Other Non Operating Income (2021 - 2026)
PepGen (PEPG) posted Other Non Operating Income of -$56000.0 for Q1 2026, down 103.64% sequentially from $1.5 million in Q4 2025, and down 1766.67% YoY from $3360.0 in Q1 2025.
Powered by 
Analysis
PepGen (PEPG) Other Non Operating Income (2021 - 2026) Analysis & Trends
PepGen has reported Other Non Operating Income for 6 years, with the latest figure at -$56000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 1766.67% year-over-year to -$56000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 3248.94% YoY) and the FY2025 annual result came in at $1.5 million, up 153400.0% from the prior year.
- Other Non Operating Income fell to -$56000.0 in Q1 2026 per PEPG's latest filing, from $1.5 million in the prior quarter.
- Over five years, Other Non Operating Income peaked at $1.5 million in Q4 2025 and troughed at -$88000.0 in Q3 2023.
- A 5-year average of $82294.1 and a median of -$3000.0 in 2025 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2023 and 2025: Other Non Operating Income slumped 2300.0% in 2023, then jumped 5819.23% in 2025.
- Over 5 years, Other Non Operating Income stood at -$28000.0 in 2022, then soared by 253.57% to $43000.0 in 2023, then plunged by 39.53% to $26000.0 in 2024, then surged by 5819.23% to $1.5 million in 2025, then plunged by 103.64% to -$56000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$56000.0, $1.5 million, and -$6000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | PepGen | 217.99 Mn | 217.99 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 50,000.00 |
| Mar 31, 2026 | -56,000.00 |
| Dec 31, 2025 | 1.54 Mn |
| Sep 30, 2025 | -6,000.00 |
| Jun 30, 2025 | 3,000.00 |
| Mar 31, 2025 | -3,000.00 |
| Dec 31, 2024 | 26,000.00 |
| Sep 30, 2024 | -39,000.00 |
| Jun 30, 2024 | -31,000.00 |
| Mar 31, 2024 | 43,000.00 |
| Dec 31, 2023 | 43,000.00 |
| Sep 30, 2023 | -88,000.00 |
| Jun 30, 2023 | -62,000.00 |
| Mar 31, 2023 | -80,000.00 |
| Dec 31, 2022 | -28,000.00 |
| Sep 30, 2022 | 4,000.00 |
| Jun 30, 2022 | 76,000.00 |
| Mar 31, 2022 | 58,000.00 |
| Dec 31, 2021 | 67,000.00 |
| Sep 30, 2021 | -34,000.00 |